Bayer’s Clock Is Ticking on Two Fronts: A Supreme Court Ruling and a Stroke Drug’s Chinese Debut

Bayer navigates a pivotal June as the US Supreme Court weighs glyphosate liability and China reviews its stroke drug Asundexian, with a $7.25B settlement on the line.

The German pharmaceutical and agricultural giant is navigating a high-stakes balancing act as June approaches. On one side, the US Supreme Court is expected to deliver a verdict by the end of that month that could determine the fate of over 100,000 glyphosate lawsuits. On the other, Bayer is pushing ahead with a critical regulatory milestone in China for its experimental stroke drug Asundexian. The stock, which closed the week at €38.05, remains roughly 22% below its February peak of €49.17, though it has still gained 58% over the past twelve months.

A Split Court Weighs Federal vs. State Authority

The oral arguments heard on April 27 in the case Monsanto v. Durnell exposed deep divisions among the justices. For nearly 90 minutes, the bench debated a fundamental tension in US federal law: the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) bars states from imposing their own labeling requirements on pesticides, yet another provision of the same law holds that EPA approvals do not constitute a binding legal mandate. Which interpretation prevails will determine the outcome of thousands of Roundup-related claims.

Chief Justice Roberts and Justice Gorsuch aligned with Justice Jackson, pressing Bayer’s legal team on whether states could hold the company liable in the same way the EPA does. The split suggests the ruling is far from a foregone conclusion. JPMorgan analyst Richard Vosser estimates the decision will have signaling effects for roughly 80% of pending glyphosate cases.

A $7.25 Billion Settlement Offer Hangs in the Balance

Bayer is not relying solely on the courtroom. In February 2026, Monsanto entered into a nationwide class-action settlement worth up to $7.25 billion, payable over 21 years to both current and future claimants. Plaintiffs have until June 4 to join the deal. A federal judge has already described the proposed settlement as a “dirty deal,” adding another layer of uncertainty.

The company has budgeted around €5 billion for legal settlements in 2026. Its net financial debt stands at nearly €30 billion. For the full year, Bayer expects adjusted EBITDA between €9.6 billion and €10.1 billion, suggesting the core business remains stable even as legal costs mount.

Asundexian Gains Traction in China

While the legal drama unfolds, Bayer’s pharmaceuticals division is making tangible progress. The Chinese drug regulator NMPA has accepted the marketing application for Asundexian, a treatment designed to prevent ischemic strokes in high-risk patients. The move marks a concrete step toward establishing Bayer’s cardiovascular pipeline in one of the world’s largest pharmaceutical markets.

Bayer plans to present 13 abstracts from its stroke portfolio at the European Stroke Organisation Conference in Maastricht from May 6 to 8, including new Phase III data from the OCEANIC-STROKE study. The conference will serve as a platform to showcase the drug’s potential ahead of a broader commercial rollout.

Regulatory Headwinds and Operational Distractions

Not all news has been positive on the regulatory front. On April 30, the FDA flagged promotional materials for the prostate cancer drug Nubeqa, citing distracting visuals and missing risk information. On the same day, Bayer recalled certain travel sizes of its Afrin Original nasal spray in the US due to a missing child-resistant closure and incomplete labeling. While both incidents are operationally manageable, they underscore the breadth of issues demanding management’s attention.

Internal Emails Add to Legal Pressure

The glyphosate saga took another turn with the disclosure of internal emails suggesting Bayer promised a “small token of appreciation” to an EPA administrator in exchange for removing cancer warnings from Roundup. The revelation is likely to further complicate the company’s legal position, even as it awaits the Supreme Court’s decision.

Analysts See Upside Despite the Risks

Despite the legal overhang, Wall Street remains cautiously optimistic. Nineteen analysts covering the stock rate it an average “Outperform,” with a consensus price target of €46.53 — roughly 22% above current levels. Whether that target holds will depend heavily on the Supreme Court’s ruling and the company’s ability to manage its debt load.

The next major checkpoint comes in May, when Bayer releases its first-quarter 2026 results. That report will offer investors a clearer view of how legal costs are impacting operational cash flow and whether the company can maintain its full-year guidance. For now, the clock is ticking on both Washington and Beijing.